No.12-26

May 18, 2012
Eisai Co., Ltd.

EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCT PORTFOLIO AND PIPELINE AT 48th ASCO ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that 15 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from June 1 to June 5, 2012. Presentations will include results from biomarker research with lenvatinib (generic name; VEGF Receptor Tyrosine Kinase Inhibitor/ Multi Kinase Inhibitor) and the first Phase I studies with E7050 (c-Met and Eph Receptor Tyrosine Kinase Inhibitor/ Multi-Kinase Inhibitor), both of which were discovered and are being developed in-house.

Eisai positions oncology as key franchise area. These studies highlight the company's current oncology product portfolio strategy and research accomplishments in this field.

Eisai seeks to achieve greater levels of innovation in oncology research through its ability to develop remarkable therapeutic hypotheses based on human biology and modern chemistry capabilities that enable it to translate these hypotheses into viable compounds, and thereby make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

The following Eisai abstracts are accepted for presentation at this year's ASCO meeting:

	Product	**Abstract Name**
1	Halaven® (Eribulin) Abstract No: TPS 1145	A Phase II Single-Arm, Feasibility Study of Dose-Dense Doxorubicin and Cyclophosphamide (AC) Followed by Eribulin Mesylate for the Adjuvant Treatment of Early-Stage Breast Cancer (EBC) *Poster Session*
2	Halaven® (Eribulin) Abstract No: 2552	A Phase 1b Dose-Escalation Study of Eribulin Mesylate in Combination with Capecitabine in Patients with Advanced/ Metastatic Cancer *Poster Session*
3	Dacogen® (Decitabine) Abstract No: 6559	Post Hoc Analysis of Relationship Between Baseline White Blood Cell Count and Survival Outcome in a Randomized Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia *Poster Session*

4	Dacogen® (Decitabine) Abstract No: 6632	Post Hoc Analysis of Relationship Between Baseline White Blood Cell Count and Renal and Hepatic Function and Response in a Randomized Phase III Trial of Decitabine in Patients Age 65 or Older with Acute Myeloid Leukemia *Poster Session*
5	Dacogen® (Decitabine) Abstract No: 6627	Post Hoc Analysis of Association Between Treatment Response and Various Indicators of Efficacy and Safety in Randomized Phase III Trial of Decitabine in Older Patients with Acute Myeloid Leukemia *Poster Session*
6	E7080 (Lenvatinib) Abstract No: TPS 4682	Treatment of Refractory Metastatic Renal Cell Carcinoma (RCC) with Lenvatinib (E7080) and Everolimus *Poster Session*
7	E7080 (Lenvatinib) Abstract No: 8594	A Phase IB Study of Lenvatinib (E7080) in Combination with Temozolomide for Treatment of Advanced Melanoma *Poster Session*
8	E7080 (Lenvatinib) Abstract No. 5518	Lenvatinib Treatment of Advanced RAI-refractory Differentiated Thyroid Cancer (DTC); Cytokine and Angiongenic Factor (CAF) Profiling in Combination with Tumor Genetic Analysis to Identify Markers Associated with Response *Poster Discussion*
9	E7080 (Lenvatinib) Abstract No:5591	A Phase II Trial of a Multitargeted Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC) *Poster Session*
10	E7050 Abstract No: 3079	A Phase I Dose-Finding Study of Golvatinib (E7050), a c-Met and Eph Receptor Targeted Multi-Kinase Inhibitor, Administered Orally BID to Patients with Advanced Solid Tumors *Poster Session*
11	E7050 Abstract No: 3030	A Phase I Dose-Finding Study of Golvatinib (E7050), a c-Met and Eph Receptor Targeted Multi-Kinase Inhibitor, Administered Orally QD to Patients with Advanced Solid Tumors *Poster Discussion*
12	MORAb-003 (Farletuzumab) Abstract No: 5062	Phase I Safety Study of Farletuzumab, Carboplatin, and Pegylated Liposomal Doxorubicin (PLD) in Patients with Platinum-Sensitive Epithelial Ovarian Cancer (EOC) *Poster Session*
13	MORAb-003 (Farletuzumab) Abstract No:3084	Phase I and Pharmacokinetic Study of Farletuzumab in Solid Tumors *Poster Session*

(Continued of following page)

14	MORAb-009 (Amatuximab) Abstract No: 7030	Amatuximab, a Chimeric Monoclonal Antibody to Mesothelin, in Combination with Pemetrexed and Cisplatin in Patients with Unresectable Pleural Mesothelioma: Results of a Multicenter Phase II Clinical Trial *Poster Discussion*
15	MORAb-004 Abstract No: 3016	A First-in-Human Phase I Study of MORAb-004 (M4), a Humanized Monoclonal Antibody Recognizing Endosialin (TEM-1), in Patients with Solid Tumors *Poster Discussion*

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120